E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Familial Chylomicronemia Syndrome (FCS) |
|
E.1.1.1 | Medical condition in easily understood language |
Familial Chylomicronemia Syndrome (FCS) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10017339 |
E.1.2 | Term | Fredrickson Type I lipidaemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060593 |
E.1.2 | Term | Fredrickson Type I lipidemia |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and efficacy of dosing and of extended dosing with volanesorsen (volanesorsen sodium 300 mg) in patients with FCS |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Able and willing to participate in a 65-week study
2. Group 1 and 2: Satisfactory completion of ISIS 304801-CS6 or ISIS 304801-
CS16 (index studies) with an acceptable safety profile, per
Sponsor and Investigator judgment
3. Group 3: Patients who did not participate in the CS6 or CS16 index
studies and meet additional inclusion criteria of Familial
Chylomicronemia Syndrome (FCS) may enroll in the study.
3a. History of chylomicronemia
3b. A diagnosis of Familial Chylomicronemia Syndrome (Type 1 Hyperlipoproteinemia)
3c. Fasting triglycerides ≥ 750 mg/dL (8.4 mmol/L) at Screening |
|
E.4 | Principal exclusion criteria |
For Group 1 and Group 2:
1. Have any new condition or worsening of existing condition which in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study
2. Unwilling to comply with lifestyle requirements for the duration of the study
For Group 3:
a. Diabetes mellitus if newly diagnosed or if HbA1c ≥ 9.0%
b. Active pancreatitis within 4 weeks of screening
c. Acute Coronary Syndrome within 6 months of screening
d. Major surgery within 3 months of screening
e. Treatment with Glybera therapy within 2 years of screening
f. Have any other conditions in the opinion of the investigator which could interfere with the patient participating in or completing the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy Endpoints:
• Percent change and absolute change from baseline in fasting TG
• Frequency and severity of patient reported abdominal pain during the treatment period
• Percent change and change from baseline in other fasting lipid measurements including total cholesterol, non-HDL-C, apoB, HDL-C,
apolipoprotein A-1 (apoA-1), VLDL-C, and LDL-C
• Percent change from baseline in fasting total apolipoprotein C-III
• Quality of Life questionnaires (EQ-5D, SF-36)
• Adjudicated acute pancreatitis event rate
• Other symptoms: eruptive xanthoma, lipemia retinalis
Safety Endpoints:
• Adverse events including adjudicated events of pancreatitis and MACE
• Vital signs and weight
• Physical examinations
• Clinical laboratory tests (serum chemistry, hematology, coagulation, urinalysis)
• Echocardiography
• Electrocardiograms (ECGs)
• Use of concomitant medications
• MRIs |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Fasting lipid measurements: Month 3 (average of W12 (D78) and W13 (D85) fasting assessments), Month 6 (average of W25 (D169) and W26 (D176) fasting assessments), and Month 12 (average of W51 (D351) and W52 (D358) fasting assessments) - For Extended Treatment Period: Month 17 (average of W70 (D484) and W74 (D512) fasting assessments), Month 21 (average of W86 (D596) and W90 (D624) fasting assessments).
Abdominal pain: Weekly from Qualification to W65
Quality of Life questionnaires: W1, 13, 26, 52, 65
AEs including acute pancreatitis, eruptive xanthoma: at each visit
Lipemia retinalis: Qualification and W52
Clinical laboratory tests: every week
Echocardiography: W26 and 52
Electrocardiograms: W13, 26, 38, 52, 65 - If Extended Treatment Period: W76 and 104
MRI: W52 |
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 15 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Canada |
France |
Germany |
Israel |
Italy |
Netherlands |
South Africa |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 9 |